A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation

Seitaro Terakura, Makoto Murata, Tetsuya Nishida, Nobuhiko Emi, Yoshiki Akatsuka, Stanley R. Riddell, Yasuo Morishima, Yoshihisa Kodera, Tomoki Naoe

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

We recently identified a human minor histocompatibility (H) antigen, encoded by UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17), whose immunogenicity results from differential expression in donor and recipient cells as a consequence of a homozygous deletion of the UGT2B17 gene. UGT2B17 is highly expressed in the liver and colon, which are major targets for graft-versus-host disease (GVHD). To assess the significance of homozygous UGT2B17 gene deletion in allogeneic haematopoietic stem cell transplantation (HSCT), we analysed DNA from 435 stem cell transplant recipients with a haematological malignancy and their human leucocyte antigen-identical unrelated bone marrow donors using sequence-specific primer polymerase chain reaction. Homozygous deletion of the UGT2B17 gene was observed in 85% of normal donors and in 82% of patients. The analysis showed no significant association between UGT2B17 mismatch in the GVHD direction and the incidence of acute GVHD, chronic GVHD, relapse, or survival. However, the use of a UGT2B17-positive donor was an independent risk factor for higher transplant-related mortality and lower survival after transplantation. UGT2B17 is a metabolic enzyme for hormones, drugs, and potentially toxic exogenous compounds and is expressed in subsets of haematopoietic cells. Thus, the enzyme function of UGT2B17 in donor cells may affect the outcome of allogeneic HSCT.

Original languageEnglish
Pages (from-to)221-228
Number of pages8
JournalBritish Journal of Haematology
Volume129
Issue number2
DOIs
Publication statusPublished - 01-04-2005

Fingerprint

Glycosyltransferases
Uridine Diphosphate
Bone Marrow Transplantation
Tissue Donors
Transplants
Peptides
Survival
Mortality
Graft vs Host Disease
Hematopoietic Stem Cell Transplantation
Minor Histocompatibility Antigens
Poisons
Gene Deletion
Hematologic Neoplasms
Enzymes
HLA Antigens
Genes
Colon
Stem Cells
Transplantation

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Terakura, Seitaro ; Murata, Makoto ; Nishida, Tetsuya ; Emi, Nobuhiko ; Akatsuka, Yoshiki ; Riddell, Stanley R. ; Morishima, Yasuo ; Kodera, Yoshihisa ; Naoe, Tomoki. / A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. In: British Journal of Haematology. 2005 ; Vol. 129, No. 2. pp. 221-228.
@article{36b1086aa60f464c841d626ef82a80ae,
title = "A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation",
abstract = "We recently identified a human minor histocompatibility (H) antigen, encoded by UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17), whose immunogenicity results from differential expression in donor and recipient cells as a consequence of a homozygous deletion of the UGT2B17 gene. UGT2B17 is highly expressed in the liver and colon, which are major targets for graft-versus-host disease (GVHD). To assess the significance of homozygous UGT2B17 gene deletion in allogeneic haematopoietic stem cell transplantation (HSCT), we analysed DNA from 435 stem cell transplant recipients with a haematological malignancy and their human leucocyte antigen-identical unrelated bone marrow donors using sequence-specific primer polymerase chain reaction. Homozygous deletion of the UGT2B17 gene was observed in 85{\%} of normal donors and in 82{\%} of patients. The analysis showed no significant association between UGT2B17 mismatch in the GVHD direction and the incidence of acute GVHD, chronic GVHD, relapse, or survival. However, the use of a UGT2B17-positive donor was an independent risk factor for higher transplant-related mortality and lower survival after transplantation. UGT2B17 is a metabolic enzyme for hormones, drugs, and potentially toxic exogenous compounds and is expressed in subsets of haematopoietic cells. Thus, the enzyme function of UGT2B17 in donor cells may affect the outcome of allogeneic HSCT.",
author = "Seitaro Terakura and Makoto Murata and Tetsuya Nishida and Nobuhiko Emi and Yoshiki Akatsuka and Riddell, {Stanley R.} and Yasuo Morishima and Yoshihisa Kodera and Tomoki Naoe",
year = "2005",
month = "4",
day = "1",
doi = "10.1111/j.1365-2141.2005.05427.x",
language = "English",
volume = "129",
pages = "221--228",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

Terakura, S, Murata, M, Nishida, T, Emi, N, Akatsuka, Y, Riddell, SR, Morishima, Y, Kodera, Y & Naoe, T 2005, 'A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation', British Journal of Haematology, vol. 129, no. 2, pp. 221-228. https://doi.org/10.1111/j.1365-2141.2005.05427.x

A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation. / Terakura, Seitaro; Murata, Makoto; Nishida, Tetsuya; Emi, Nobuhiko; Akatsuka, Yoshiki; Riddell, Stanley R.; Morishima, Yasuo; Kodera, Yoshihisa; Naoe, Tomoki.

In: British Journal of Haematology, Vol. 129, No. 2, 01.04.2005, p. 221-228.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A UGT2B17-positive donor is a risk factor for higher transplant-related mortality and lower survival after bone marrow transplantation

AU - Terakura, Seitaro

AU - Murata, Makoto

AU - Nishida, Tetsuya

AU - Emi, Nobuhiko

AU - Akatsuka, Yoshiki

AU - Riddell, Stanley R.

AU - Morishima, Yasuo

AU - Kodera, Yoshihisa

AU - Naoe, Tomoki

PY - 2005/4/1

Y1 - 2005/4/1

N2 - We recently identified a human minor histocompatibility (H) antigen, encoded by UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17), whose immunogenicity results from differential expression in donor and recipient cells as a consequence of a homozygous deletion of the UGT2B17 gene. UGT2B17 is highly expressed in the liver and colon, which are major targets for graft-versus-host disease (GVHD). To assess the significance of homozygous UGT2B17 gene deletion in allogeneic haematopoietic stem cell transplantation (HSCT), we analysed DNA from 435 stem cell transplant recipients with a haematological malignancy and their human leucocyte antigen-identical unrelated bone marrow donors using sequence-specific primer polymerase chain reaction. Homozygous deletion of the UGT2B17 gene was observed in 85% of normal donors and in 82% of patients. The analysis showed no significant association between UGT2B17 mismatch in the GVHD direction and the incidence of acute GVHD, chronic GVHD, relapse, or survival. However, the use of a UGT2B17-positive donor was an independent risk factor for higher transplant-related mortality and lower survival after transplantation. UGT2B17 is a metabolic enzyme for hormones, drugs, and potentially toxic exogenous compounds and is expressed in subsets of haematopoietic cells. Thus, the enzyme function of UGT2B17 in donor cells may affect the outcome of allogeneic HSCT.

AB - We recently identified a human minor histocompatibility (H) antigen, encoded by UDP glycosyltransferase 2 family, polypeptide B17 (UGT2B17), whose immunogenicity results from differential expression in donor and recipient cells as a consequence of a homozygous deletion of the UGT2B17 gene. UGT2B17 is highly expressed in the liver and colon, which are major targets for graft-versus-host disease (GVHD). To assess the significance of homozygous UGT2B17 gene deletion in allogeneic haematopoietic stem cell transplantation (HSCT), we analysed DNA from 435 stem cell transplant recipients with a haematological malignancy and their human leucocyte antigen-identical unrelated bone marrow donors using sequence-specific primer polymerase chain reaction. Homozygous deletion of the UGT2B17 gene was observed in 85% of normal donors and in 82% of patients. The analysis showed no significant association between UGT2B17 mismatch in the GVHD direction and the incidence of acute GVHD, chronic GVHD, relapse, or survival. However, the use of a UGT2B17-positive donor was an independent risk factor for higher transplant-related mortality and lower survival after transplantation. UGT2B17 is a metabolic enzyme for hormones, drugs, and potentially toxic exogenous compounds and is expressed in subsets of haematopoietic cells. Thus, the enzyme function of UGT2B17 in donor cells may affect the outcome of allogeneic HSCT.

UR - http://www.scopus.com/inward/record.url?scp=17644379006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17644379006&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2005.05427.x

DO - 10.1111/j.1365-2141.2005.05427.x

M3 - Article

C2 - 15813850

AN - SCOPUS:17644379006

VL - 129

SP - 221

EP - 228

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -